Innovations In Medicine
Leading clinicians, scientific experts, and medical affairs professionals explore emerging developments across medicine and biotechnology, translating new evidence and scientific advances into insights that inform clinical decision-making and future standards of care.
1-15 of 18
On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Project Oncology®On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Charles Turck, PharmD, BCPS, BCCCP
Jun Gong, MD
Challenging Cases in IgA Nephropathy and Identifying Patients for Specialized Care
Medical Industry FeatureChallenging Cases in IgA Nephropathy and Identifying Patients for Specialized Care
Jaimini Patel, PharmD, BCCCP
Sayna Norouzi, MD
How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
Project Oncology®How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
Alexandria May, PharmD, BCPS
Sunnie Kim, MD
Agitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Medical Industry FeatureAgitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Charles Turck, PharmD, BCPS, BCCCP
George Grossberg, MD
Angela Sanford, MD, CMD
Courtney Crawford, MD, FACS
Raj Maturi, MD
Tau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers
Medical Industry FeatureTau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers
Yuval Zabar, MD
Michelle Mielke, PhD
Henrik Zetterberg, MD, PhD
- advertisement
Amyloid and Tau in Alzheimer’s Disease: Insights into Disease Progression
Medical Industry FeatureAmyloid and Tau in Alzheimer’s Disease: Insights into Disease Progression
Holly M. Brothers, PhD
Niklas Mattsson-Carlgren, MD, PhD
Navigating IgA Nephropathy: Pathogenesis, The Role Of APRIL & The 4-Hit Process, & A Patient Case Study
Medical Industry FeatureNavigating IgA Nephropathy: Pathogenesis, The Role Of APRIL & The 4-Hit Process, & A Patient Case Study
Abigail Yancey, PharmD, BCPS
Kartik Kalra, MD
Diagnosing IBS-C: From Clinical Clues to Confident Calls
Clinician's RoundtableDiagnosing IBS-C: From Clinical Clues to Confident Calls
Darren Brenner, MD
Kyle Staller, MD, MPH
MIRASOL Insights in PROC: A Biomarker-Driven Approach
Project Oncology®MIRASOL Insights in PROC: A Biomarker-Driven Approach
Charles Turck, PharmD, BCPS, BCCCP
Cecelia Boardman, MD
Immunotherapy Advances in Early-Stage Upper GI Cancers: Key Trial Insights
Project Oncology®Immunotherapy Advances in Early-Stage Upper GI Cancers: Key Trial Insights
Jennifer Caudle, DO, FACOFP
Ronan J. Kelly MD, MBA, FASCO
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
Clinician's RoundtableImproving Survival and Function in Pediatric TK2d with Nucleoside Therapy
Charles Turck, PharmD, BCPS, BCCCP
Caterina Garone, MD, PhD
- advertisement
Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
Clinician's RoundtableUncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
Charles Turck, PharmD, BCPS, BCCCP
Cristina Domínguez González, MD, PhD
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
Clinician's RoundtableUnderstanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
Charles Turck, PharmD, BCPS, BCCCP
Philip Yeske, PhD
Investigator Perspectives on Treating Patients in a Ph2 NSCLC Trial
Project Oncology®Investigator Perspectives on Treating Patients in a Ph2 NSCLC Trial
Jennifer Caudle, DO, FACOFP
D. Ross Camidge, MD, PhD
Jonathan Goldman, MD
